NuProbe USA, Inc. – Trademark Portfolio
Entity Type: 03
NuProbe USA, Inc. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 6 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include AUGURY, NGSURE, VARMAP, NUPROBE, and VARTRACE. The owner is based in Houston, TX.
2575 West Bellfort Avenue, Ste. 200
Houston, TX 77054
Showing of trademarks Trademarks
Trademark Classifications
NuProbe USA, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does NuProbe USA, Inc. have?
NuProbe USA, Inc. has 8 U.S. trademarks filed with the USPTO. Of these, 5 registered, 3 abandoned.
What trademark classes does NuProbe USA, Inc. file in?
NuProbe USA, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are NuProbe USA, Inc.'s most well-known trademarks?
NuProbe USA, Inc.'s registered trademark portfolio includes well-known marks such as AUGURY, NGSURE, VARMAP, NUPROBE, and VARTRACE. These are among 5 currently registered trademarks in the portfolio.
What is NuProbe USA, Inc.'s trademark registration success rate?
NuProbe USA, Inc. has a 63% trademark registration rate, with 5 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.